The BATURA trial ended early due to high efficacy data at pre-planned analysis. Topline results were announced from a phase 3b trial evaluating albuterol/budesonide metered dose inhaler in patients ...
DENVER — National Jewish Health researchers are looking for ways to identify patients with untreated mild persistent asthma who might benefit from daily inhaled treatment based on inflammatory ...
Please provide your email address to receive an email when new articles are posted on . BATURA showed a 47% reduction in severe exacerbation risk with albuterol budesonide vs. albuterol in patients ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AIRSUPRA’s US Prescribing Information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma. 1 The BATURA Phase IIIb trial, ...
Hosted on MSN
How asthma is treated
Asthma action plans help maintain good asthma control by outlining symptoms, triggers, medications, and emergency contacts. Avoiding triggers, such as allergens and tobacco smoke, can help prevent ...
CHICAGO, May 16 (Reuters) - People whose mild asthma is under control may be able to safely step down to a daily treatment, researchers said on Wednesday. Sign up here. Current treatment guidelines ...
Independent Data Monitoring Committee recommended trial stop early due to overwhelming efficacy at pre-planned analysis AstraZeneca’s inhaled anti-inflammatory rescue medication AIRSUPRA demonstrated ...
After winning a first-in-class nod for its two-drug inhaler Airsupra last January, AstraZeneca is adding to the thesis that the drug can cut the risk of asthma exacerbations regardless of disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback